Celltrion
Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea.
| Company type | Public |
|---|---|
Traded as | KRX: 068270 |
| Industry | Biopharmaceutical |
| Founded | 2002 |
| Founder | Seo Jung-jin |
| Headquarters | Yeonsu-gu, Incheon, South Korea |
Area served | Worldwide |
Key people | Seo Jung-jin, Chairman Kee Woo-sung, CEO |
| Products | Remsima™, Truxima™, Herzuma™, Biosimilar Drug |
| Revenue | ₩828,917 million (2017) |
| ₩517,385 million (2017) | |
Net income | ₩403,181 million (2017) |
| Total assets | ₩3,255,319 million (2017) |
| Total equity | ₩2,522,076 million (2017) |
| Owner | Celltrion Holdings Co., Ltd. (23.03%) Ion Investments B.V. (9.54%) National Pension Service (6.07%) |
| Subsidiaries | Celltrion Entertainment |
| Website | www |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.